Condition
Premenstrual Dysphoric Disorder (PMDD)
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Recruiting2
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06704594Phase 4RecruitingPrimary
Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder
NCT06771583Recruiting
Identification and Validation of Epigenetic Biomarkers of PMDD
NCT01945372Not ApplicableUnknown
Neurofeedback Treatment of Affective Instability in Premenstrual Dysphoric Disorder(PMDD)
NCT00824187Phase 3CompletedPrimary
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
Showing all 4 trials